Expert Rev Mol Diagn. 2008;8(4):417-434. Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone. There is therefore ...

Iambic Therapeutics has initiated the dosing of the first subject in its Phase I/Ib clinical trial of IAM1363, a novel therapeutic agent targeting human epidermal growth factor receptor 2 (HER2 ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

The extracellular domain of HER2 is unable to bind extracellular ligands and depends on heterodimerization with other ligand-activated receptors like EGFR. 3 ...the combination of lapatinib plus ...

BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations that are seen in NSCLC tumours. The oral drug was awarded ...

BMBC is particularly common in breast cancers that are positive for epidermal growth factor receptor1 and 2 (EGFR and HER2), however, targeted therapies against BMBC, e.g., lapatinib - a EGFR/HER2 ...

Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 receptor, and lapatinib, a dual reversible EGFR/HER2 TKI, are indicated for the treatment of HER2 ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...